ConductScience.org, home

Comparison · NCT05965427-sae

PLWHIV and Mpox Coinfection vs HIV Negative PrEP Users With Mpox Infection: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. PLWHIV and Mpox Coinfection vs HIV Negative PrEP Users With Mpox Infection: serious adverse events. Trial comparisons, record NCT05965427-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05965427-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.06030.04680.0773wilson
Risk in group 20.03610.02640.0491wilson
Risk difference, group 1 minus group 20.02420.005460.0438newcombe hybrid score
Risk ratio, group 1 over group 21.671.122.5log
Odds ratio, group 1 over group 21.711.132.61log
Number needed to harm, for one more participant with a serious adverse event on PLWHIV and Mpox Coinfection than on HIV Negative PrEP Users With Mpox Infection41.322.8183from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1PLWHIV and Mpox CoinfectionPeople living with HIV (PLWHIV) who are at least 18 years of age, with confirmed MPX infection by documented, positive result on PCR testing of lesions from 1st May 2022 to 1st December 2023.57946EG000
Group 2HIV Negative PrEP Users With Mpox InfectionPrEP (Pre-exposure prophylaxis) users who are at least 18 years of age, with confirmed MPX infection by documented, positive result on PCR testing of lesions from 1st May 2022 to 1st December 2023.381,054EG001

Harm

What it counts
Total, serious adverse events
Time frame
From date of disease onset/first symptom, D0, until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months) D90

Source ClinicalTrials.gov

Trial

Title
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
NCT number
NCT05965427
Phases
Conditions
Monkeypox, HIV Coinfection
Interventions
No intervention
Lead sponsor
NEAT ID Foundation
Results first posted
2025-08-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05965427-sae